Prostate cancer screening recommendations have undergone a major change, with the American Cancer Society (ACS) now advising routine screening for many men to help detect the disease earlier and reduce cancer-related deaths.

The updated guidelines, published in CA: A Cancer Journal for Clinicians, mark a significant shift from the society's 2010 recommendations, which focused on helping men decide whether to undergo screening after discussing the potential benefits and risks with their doctors.

According to the ACS, advances in screening, diagnosis and treatment have improved the balance between the benefits and potential harms of prostate cancer screening. The revised recommendations focus on prostate-specific antigen (PSA) blood testing, with screening frequency determined by age and individual risk factors.

Here are the top key takeaways from the updated ACS prostate cancer screening guidelines:

  1. Routine screening for men aged 50–69 years: Men at average risk of prostate cancer are advised to undergo PSA blood testing every two years.
  2. Annual screening for men with a family history: Men with a family history of prostate cancer are advised to undergo annual PSA screening.
  3. Individual decisions for men aged 70–74 years: The benefits and risks of screening remain uncertain in this age group. Men should discuss their individual health status and screening options with their doctors.
  4. Screening generally not recommended after 75 years: Routine screening is not recommended for men aged 75 and older. However, selected healthy men aged 75–79 may consider continued screening, particularly if previous PSA levels have been increasing.
  5. No screening for men aged 80 years and older: Screening is not recommended for men aged 80 and above or those with a life expectancy of less than 10 years.
  6. Repeat PSA testing and MRI before biopsy: The guidelines recommend confirming elevated PSA levels with another blood test and obtaining magnetic resonance imaging before proceeding to a prostate biopsy.
  7. Active surveillance for low-risk prostate cancer: Men diagnosed with low-risk disease should initially be offered close monitoring rather than immediate surgery or radiation treatment when appropriate.
  8. Patients should understand screening benefits and risks: Although routine screening is now recommended for many men, doctors should continue explaining potential benefits, false-positive results, unnecessary biopsies and treatment-related complications.

The ACS noted that improvements in diagnostic techniques, robotic surgery, targeted radiation therapy and active surveillance have helped reduce some of the harms historically associated with prostate cancer screening.

REFERENCE: Hoffman RM, Wolf AMD, Etzioni RD, et al. American Cancer Society guideline for the early detection of prostate cancer, 2026. CA Cancer J Clin. 2026;e70112. doi:10.3322/caac.70112

Full View
Tags:    
Article Source : CA: A Cancer Journal for Clinicians

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .